Companies Dominating the Wearable Cardioverter Defibrillators Landscape
- ZOLL Medical Corporation
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Element Science Inc.
- Medtronic plc
- Kestra Medical Technologies, Inc.
- Abbott
- Boston Scientific Corporation
- LivaNova plc
- Koninklijke Philips N.V.
- Nihon Kohden Corporation
- General Electric Company.
Browse Key Market Insights with Data Illustration:
In the News
- Medtronic plc announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) for Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan to offer the advantages of conventional, transvenous ICDs in terms of saving lives by providing anti-tachycardia pacing (ATP), backup (pause-prevention) pacing therapy, and life-saving defibrillation.
- Abbott received approval from the U.S. Food and Drug Administration (FDA) for Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices with Bluetooth technology and a new patient smartphone app for better remote monitoring for patients with cardiac rhythm abnormalities.